Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stock Watch: Novartis Softens Up The Market For BMS And Sanofi

Third-Quarter Earnings Suddenly Get Worse

Executive Summary

Earnings season was not going too badly until a spate of self-inflicted wounds by BMS and Sanofi soured sentiment. Many new product launches remained too small to help.

You may also be interested in...

Sanofi Stock Slides On Lower Profit Forecast And Consumer Health Spinoff Plan

The French drugmaker is significantly upping its R&D spend and exiting consumer care, a strategy CEO Paul Hudson has stoutly defended following a slump in the share price.

Stock Watch: Positive Q3 For Johnson & Johnson Post-Kenvue

J&J’s separation from its consumer division increased its cash, reduced its share count and provided interest income greater than third-quarter worldwide sales of some of its new drugs.

Stock Watch: Where Novo And Lilly Lead, Others Follow

AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts